Biomarker‐based risk prediction in the community

Guided by predictive characteristics of cardiovascular biomarkers, we explored the clinical implications of a simulated biomarker‐guided heart failure (HF) and major adverse cardiovascular events (MACE) prevention strategy in the community.

[1]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[2]  H. Soran,et al.  Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. , 2015, European heart journal.

[3]  W. Qureshi,et al.  Risk Stratification for Primary Prevention of Coronary Artery Disease: Roles of C-Reactive Protein and Coronary Artery Calcium , 2015, Current Cardiology Reports.

[4]  L. Tilson,et al.  Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study , 2015, European journal of heart failure.

[5]  M. Pencina,et al.  Charting a roadmap for heart failure biomarker studies. , 2014, JACC. Heart failure.

[6]  A. Jaffe,et al.  High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. , 2014, Clinical chemistry.

[7]  V. Salomaa,et al.  ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality , 2014, Heart.

[8]  R. McKelvie,et al.  Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review , 2014, Heart Failure Reviews.

[9]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[10]  E. Barrett-Connor,et al.  Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. , 2014, American heart journal.

[11]  R. D. de Boer,et al.  Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort , 2014, Circulation. Heart failure.

[12]  J. Gaziano,et al.  Plasma galectin 3 and heart failure risk in the Physicians' Health Study , 2014, European journal of heart failure.

[13]  V. Salomaa,et al.  High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. , 2014, European heart journal.

[14]  R. Prager,et al.  PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.

[15]  C. Watson,et al.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.

[16]  L. Lind,et al.  Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. , 2013, Journal of the American College of Cardiology.

[17]  D. Levy,et al.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.

[18]  D. Levy,et al.  Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.

[19]  Hanyu Ni,et al.  Prediction of Incident Heart Failure in General Practice: The Atherosclerosis Risk in Communities (ARIC) Study , 2012, Circulation. Heart failure.

[20]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[21]  Olle Melander,et al.  Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[22]  D. Levy,et al.  Multimarker Approach for the Prediction of Heart Failure Incidence in the Community , 2010, Circulation.

[23]  K. Bailey,et al.  The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. , 2010, Journal of the American College of Cardiology.

[24]  K. Bailey,et al.  Participation bias in a population-based echocardiography study. , 2004, Annals of epidemiology.

[25]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[26]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[27]  John O'Quigley,et al.  An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .

[28]  L. Melton,et al.  History of the Rochester Epidemiology Project. , 1996, Mayo Clinic proceedings.

[29]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[30]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[31]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.